Summary.-Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemotherapy which included daunorubicin, cytosine arabinoside and 6-thioguanine (DAT). The complete remission rate was 85o% and was achieved, in responsive cases, after an average of 2 courses of therapy. Patients remained in hospital for an average of 37*5 days during remission-induction therapy and 3-7 days per month thereafter. The median remission period was 48 weeks and median survival was 70 weeks. A disappointing feature was the high relapse rate. This feature of the results re-affirms the need for a more effective form of remission therapy.
THE treatment of AML continues to present the most difficult challenge to the haematological oncologist, with many series underlining the contrast between the success rates in AML and in acute lymphatic leukaemia. Some recent reports, however, have given grounds for more optimism (Gale and Cline, 1977; Uzuka, Liong and Yamagata, 1976; McCredie et al., 1974) . We report here the results of treating 20 consecutive cases of AML with a combination of cytotoxic drugs which included daunorubicin, cytosine arabinoside and 6-thioguanine (DAT). All the patients were treated at Addenbrooke's Hospital, Cambridge.
PATIENTS AND METHODS
Treatment protocol.-The basic remission protocol is shown in Fig. 1 .
The regime combines the use of daunorubicin, a cell-cycle stage-nonspecific drug, with the 2 synergistic cell-cycle stagespecific drugs, cytosine arabinoside and 6-thioguanine. Twelve-hourly rather than 24-hourly use of the latter combination, as advocated by Clarkson (1972) , and earlier used at the Sloan-Kettering Institute in the L6 protocol, appears to offer an advantage. Our own experience with that protocol, in which the 12-hourly combination was continued until a state of marrow hypoplasia developed, had suggested that myelosuppression tended to be unduly severe, and we therefore prefer to restrict treatment with the DAT protocol initially to a 5-day period. In the exceptional patient whose leukaemic-cell population is not sharply depressed by the (nil) Patients in the series. The patients treated with the DAT regime had not previously received anti-leukaemia therapy. They were referred by local general practitioners and other hospital departments in the area. In this respect, the department acts as a primary or secondary referal centre (Hayhoe, 1975) and, as such, some selection of cases may have been made before entering our care. No selection was made following referal. The morphological diagnosis was made using well-established cytochemical characteristics (Hayhoe and Flemans, 1969) . There were 7 cases of AML, 9 cases of acute myelomonocytic leukaemia (AMML), 2 cases of erythroleukaemia, one acute monocytic (AMo) and one promyelocytic (ProMy) leukaemia.
There wN-ere 10 men and 10 wiomen wAith an average age of 47 years (range 17-66). The results of the haematological studies performed at the time of admission are shown in Table 1 .
Suppportire care. Blood transfusions w-ere given when the haemoglobin level fell belowN 8-0g/dl. Platelet, transfusions, wNhich wNere freely available from the Regional Blood Transfusion Service situated within the hospital grounds, wNere given wrhen thrombocytopenia was combined with clinical evidence of bleeding, unless previous experience w itlh an individual patient had led us to expect bleeding belowN a certain platelet level. Granulocyte transfusions from unrelated ABO-compatible, partially HLA-compatible, donors were given to Patients 11 and 19 during episodes of high fever (>390C) and severe leucopenia (total WBC <0 5 x 109/1). Granulocyte transfusions wAere not available during the first year of the study.
The patients were treated in single rooms whlen possible, or in 3-or 10-bed wA-ards shared wAith other general medical patients. Access to protected environments was not generally available and patients w%ere allowsed to move freely about the ward Ahen not obviously harbouring an infection. A great deal of attention w%as paid to dental and oral care.
Extractions or conservative t,reatment of carious teeth were carried out as an elective procedure wN\hen remission had been achieved.
ln the intervening period regular attention from a dental hygienist was provided. The use of a bacteriostatic mouth-wash and dental brushing following each meal helped to decrease the incidence of gingival and oral infections. (Gale and Cline, 1977; Uzuika et al., 1976) .
The average number of courses of therapy requiired to reach a remuission was 2, and no patient achieviing remission reqttiredl more than 3. This feature of the response has led us to be pessimistic over the chanices of remission if it lecomes necessary to begin a fourth course withotut comnplete remission having been reached. The (Iuration of remission raniged from 6 to 72 weeks, with a median value of 48 weeks. The actuarial curve of duration of remnissioIn is showni in Fig. 2 Quality of sarvival The quality of survival in patients with leukaemia is an important factor when considering the efficacy of a treatment regime, and has received a great deal of attention recently (Burge et al., 1975 NR-PR = 100 h- 6 and 8) achieved prolonged second remissions aiid returned to work following the re-induction therapy. The number of courses for reinduction of remission in this small group was 2, 1 and 2 respectively. These were obtained after an average of 28 days from the diagnosis of relapse. Four patients failed to gain a second remission (Nos. 4, 5, 13 and 17).
Causes of death
Eight patients have died during the course of this study, but there was only one early death (less than 6 weeks after diagnosis). All were in relapse at the time of death, apart from Patient No. 3 who died at home in remission with pneumonia which was presumed to be viral.
The causes of death in the remaining 7 patients were infection in 6 (3 Gramnegative septicaemia, one systemic candidiasis, 2 staphylococcal septicaemia and one with an unidentified organism). One patient died of a cerebellar haemorrhage. All patients were severely neutropenic (neutrophil count <500/cm3) at the time of death, and all had severe thrombocytopenia. No granulocyte transfusions were given to these patients, because no facilities for such provision were available during the early part of the study. In our experience, haemorrhage is an uncommon cause of death, and in Patient 13 cerebellar haemorrhage occurred at a time of hectic fever. Others have reported similarly low incidence of haemorrhage as a terminal event (Smith, Powles and McElwain, 1976) .
Prognostic featwres
The value of clinical feattures and results of laboratory studies in forecasting the outcome in an individual case of leukaemia has recently been reviewed by Gehan et al. (1976) . Galton, Howard and Pike (1975) have drawn attention to the decreased survival with advancing age and the unfavourable effect of a low platelet count. These features were not associated with poorer results in our series. The presence or absence of Auer rods in AML has conflicting prognostic value Henderson et al., 1975 
DISCUSSION
The treatment protocol which has been described has produced a remission rate of 85% in previously untreated patients with AML of all age groups. With a relatively small series it is difficult to draw any conclusions from the cases of those patients who did not enter remission; however 2 of the patients were aged 66 and the other was a case of erythroleukaemia in which the abnormal erythroid population rapidly disappeared with the frst course of therapy, leaving a resistant myeloid series to emerge from a severely hypoplastic marrow.
It is now becoming increasingly evident that combinations of cytotoxic therapy using adriamycin or daunorubicin, together with cytosine arabinoside, 6-thioguanine or 6-mercaptopurine, with or without prednisone, have great potential value. The most successful series recentlyreported (Gale and Cline, 1977; Uzuka et al., 1976; McCredie et al., 1974; Henderson et al., 1975) have all used a minimum of 3 drugs from this group, and they have become essential components around which to plan future therapy. The 4 series referred to, when taken with ours, produce an average remission rate of 79%. Since remission rates at this level have been achieved only recently and in few centres, experience with maintenance therapy has been difficult to accumulate, and our series does little to expand or improve the results in this area. The median duration of first remission of 48 weeks is comparable with those of most of the more successful series, but its disappointing brevity reflects the lack of a satisfactory maintenance regime. Of the 7 patients in our series who relapsed, 3 attained an easy second remission.
A major problem in the management of leukaemic patients continues to be infection. The prompt investigation and treatment of pyrexia in these patients is recognized by nursing, medical and laboratory staff to be of paramount importance. Gale and Cline (1977) and ourselves. Another factor which may have contributed to the lower success rate in some large-scale trials is the apparent lack of flexibility in the protocols, which are sometimes followed too literally by the contributing physicians. We have adopted a flexible policy of tailoring the amount and duration of our therapy to the needs of individual patients. This may not provide a very easy basis on which to run a large-scale trial but we believe it encourages higher remission and survival rates. This is not a novel approach, and adjustments in our series have been few and small, but we think that they have been valuable. The therapy is for the most part well tolerated, the only unpleasant side-effect in some patients being nausea, which is controlled to an acceptable level by anti-emetic therapy.
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